Aprinoia Therapeutics
Latest round
- Series C
Last raised
- Dec 2021
Total raised
- $51M
Investors
- 7
About Aprinoia Therapeutics
Founded in 2015 by Ming-Kuei Jang and based in Grand Cayman, Cayman Islands, Aprinoia Therapeutics Inc. operates as a drug developer for neurodegenerative diseases, focusing on the research and development of new drugs for neurodegenerative diseases. In December 2021, Aprinoia Therapeutics Inc., including IMM Investment, Harvest Capital, KTB Network, and TaiAn Technologies Corporation. Shearman. The company also has offices in the US, Hong Kong, China, and Japan. The company focuses on neurodegenerative diseases, which include disorders such as Alzheimer's disease, Parkinson's disease, and other tauopathies. The product pipeline includes [18F]-APN-1607 Florzolotau (18F), aSyn PET Tracer, APNmAb005, Tau Degrader, and aSyn Degrader. The firm’s pipeline comprises several diagnostic and therapeutic programs. On the diagnostic front, the company is advancing imaging agents designed to improve the early detection and monitoring of neurodegenerative diseases. These agents enable accurate diagnosis and tracking of disease progression, guiding patient management and treatment decisions. In terms of therapeutics, Aprinoia is developing treatments aimed at halting or slowing disease progression. Their therapeutic candidates target pathological proteins, aiming to modify the underlying disease mechanisms rather than just alleviating symptoms. The company also collaborates with academic institutions, healthcare providers, and industry partners to accelerate the translation of their research into clinical practice.
Who invested in Aprinoia Therapeutics
7 investors across 2 rounds
See all investors in Aprinoia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aprinoia Therapeutics
Who invested in Aprinoia Therapeutics?
Aprinoia Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aprinoia Therapeutics raised?
Aprinoia Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aprinoia Therapeutics last raise money?
Aprinoia Therapeutics's most recent round on record is a Series C, in Dec 2021.
What does Aprinoia Therapeutics do?
Founded in 2015 by Ming-Kuei Jang and based in Grand Cayman, Cayman Islands, Aprinoia Therapeutics Inc.
Where is Aprinoia Therapeutics headquartered?
Aprinoia Therapeutics is headquartered in Grand Cayman, Cayman Islands.
Which VCs invest in companies like Aprinoia Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Aprinoia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Aprinoia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.